Computer-Aided Diagnosis for Hepatocellular Carcinoma Microvascular Invasion

Recruiting Observational Study
Hepatocellular Carcinoma (HCC) Microvascular Invasion (MVI)
No Placebo Group Every participant receives an active treatment — no one gets a placebo. No Study Drug Researchers observe your health over time — no experimental treatment is given.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Age
18 – 18
Sex
Any
Study type
Observational
Participants needed
400 (estimated)
Sponsor
Chinese Academy of Sciences · Government
Think this trial could be right for you?

Answer a few quick questions to see if you may meet the eligibility requirements.

Check Your Eligibility
About This Trial
Hepatocellular carcinoma (HCC) is a common malignancy in China with a high mortality rate. Its early recurrence and long-term prognosis are closely associated with tumor aggressiveness. Microvascular invasion (MVI), defined as the presence of tumor cells within small branches of the portal or hepatic veins, is a key indicator of malignant biological behavior in HCC. Clinically, MVI is strongly cor…
Trial Locations
Loading…

Loading trial locations…

Eligibility Criteria
Inclusion Criteria: * Age ≥ 18 years. * Confirmed diagnosis of hepatocellular carcinoma (HCC) according to the Chinese Clinical Practice Guidelines for Primary Liver Cancer. * Eligible for surgical intervention (hepatic resection or liver transplantation) according to the Chinese Clinical Practice …
Contacts

Di Dong, Ph.D.

+86 13811833760

di.dong@ia.ac.cn

CONTACT

Mengjie Fang, Ph.D.

+86 18500909634

fangmengjie2015@ia.ac.cn

CONTACT